In every war, there comes a moment when the map of targets stops looking like a map of the front and starts looking like a diagram of everyday life. No longer missile depots, air bases or command centers, but the systems without which a city may still stand while no longer functioning as a place to live. That is what a strike on a pharmaceutical facility represents. It may still be framed in military language, but its consequences move almost immediately into hospitals, operating rooms, supply chains and the anxieties of civilians.
The attack on Tofigh Daru in Tehran belongs to that category. Israel presented it as a strike on a site allegedly tied to military activity and hidden behind a civilian facade. Iran, by contrast, described it as a blow to the health system, insisting that the factory produced raw materials for hospital drugs, operating-room medicines and some cancer treatments. The disagreement is not simply factual. It opens a much larger question about what modern states now consider a legitimate target.
That is what makes the episode so consequential. In contemporary war, few categories are more elastic than the “dual-use” object. Once a government asserts that a civilian facility was partly supporting the military sector, an old line begins to blur. The issue then is no longer whether such a claim can be made. The issue is what concrete military advantage is being gained, and what is being destroyed in real civilian terms.
In Deykom’s assessment, the strike on Tofigh Daru matters not only as a single incident but as a symptom of a broader transformation in warfare. Twenty-first-century conflicts are moving steadily away from the clear geometry of the battlefield and into the texture of civilian maintenance itself. Energy grids, water systems, logistics routes, telecommunications networks, medical supply chains: these are no longer merely the background conditions of war. They have become extensions of it. And the more complex an economy becomes, the harder it is to separate military usefulness from civilian indispensability.
International humanitarian law, at least in principle, remains quite clear. Only military objectives may be attacked, not civilian objects as such. Even where an object may plausibly be considered dual-use, the attacking force is still bound by the obligations of distinction and proportionality. That means verifying the target, minimizing civilian harm and refraining from attack if the expected damage to civilians is excessive in relation to the anticipated military gain. Which is precisely why the Tehran strike raises such an uncomfortable question: can the destruction of a pharmaceutical production hub be called proportionate if its immediate and unavoidable effect is pressure on civilian care?
The problem is that pharmaceutical infrastructure is not just another industrial asset. It does not sit in the economy the way a warehouse or a metalworks plant does. It exists as part of a system of survival. A destroyed raw-material unit is not merely a financial loss to its owner. It means delayed deliveries to hospitals, disruptions in production lines, mounting shortages, higher prices and more stress on a medical system that was already operating under strain. In such a case, the civilian effect is not incidental. It is built into the strike itself.
That context matters even more in Iran, where years of sanctions, currency pressure and barriers to importing medicine and medical inputs have already pushed the country toward domestic production. Formally, humanitarian goods are not meant to be fully excluded from international exchange. In practice, financial restrictions, overcompliance and procurement bottlenecks have made access to medicines and pharmaceutical components far more difficult than legal language suggests. In that environment, domestic plants do not simply supplement the market. They hold it together. When one of them is hit, the effect is not isolated. It spreads.
Which is why the Israeli claim regarding possible military use of certain substances does not settle the matter. At most, it moves the debate onto more dangerous ground. Even if some compounds produced at the site could also have served a non-civilian purpose, that does not automatically make the wholesale destruction of the facility legally or morally persuasive. This is the central risk of the dual-use argument: it can become a standing permission slip for attacks on systems whose primary function remains civilian.
In the case of Tofigh Daru, the contradiction is especially sharp. If the military benefit was possible or inferred, but the civilian damage was certain, then the moral geometry changes. The issue is no longer whether civilian infrastructure was masking military utility. The issue becomes whether military rationale is being used to justify the destruction of civilian capacity. At that point, proportionality stops being an abstract legal doctrine and becomes a very plain question: what, in practice, was this strike really aimed at?
There is also a distinct psychological dimension to attacks of this kind. Societies have learned, however reluctantly, to interpret strikes on energy systems, bridges or transport routes as part of the familiar language of war. But when the target is pharmaceutical production, the signal changes. The vulnerability is no longer only national or strategic. It becomes bodily. War moves not just into the news cycle or the sound of explosions, but into the fear of whether medicine will still be available for surgery, emergency care or cancer treatment. The threat becomes intimate.
That is why this episode should be read as more than one controversial strike inside a broader campaign. It reveals how modern states increasingly pressure their adversaries through infrastructures that are at once civilian in function and arguable in military relevance. This is one of the most dangerous gray zones of contemporary war. It allows force to be applied without openly declaring civilians to be the object, while ensuring that civilians cannot remain outside the consequences. The more technologically dense a society becomes, the more such targets exist.
For Iran, the consequences are especially severe because the medical market was already fragile. A system burdened by shortages, currency constraints, disrupted procurement and rising prices does not absorb the destruction of a major production site as a manageable shock. It transmits it. The loss travels down the chain, from industrial inputs to hospital shelves, from factories to operating rooms, from macroeconomics to the smallest decisions about treatment.
But the precedent is not risky only for Iran. It is risky for Israel and its allies as well. The more expansively the concept of military objective is interpreted, the weaker any future argument becomes for shielding one’s own civilian infrastructure from the same logic in return. War always tempts states to believe their exceptions are special. Law exists precisely to prevent exceptions from hardening into norms. If a pharmaceutical factory can be demolished on the basis of an asserted military link, then the same reasoning can in time be extended to water purification, food processing, transport systems or other foundations of civilian life.
What the strike on Tofigh Daru ultimately exposes is an uncomfortable truth about contemporary war: the most consequential targets increasingly do not look military at all. They are embedded in the ordinary architecture of social existence. That is why the line between a legitimate strike and an attack on civilian life is becoming thinner, not clearer. And that is why the argument over this factory in Tehran is far larger than a single operation. It is an argument about whether the law of war still has the power to restrain conflict at the very moment when conflict is learning how to hide inside technical justifications.
